Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $161,000.00 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $16.10, for a total transaction of $161,000.00. Following the completion of the sale, the insider now owns 1,057,535 shares in the company, valued at approximately $17,026,313.50. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Day One Biopharmaceuticals Stock Down 1.4 %

NASDAQ DAWN traded down $0.22 during trading hours on Tuesday, hitting $15.64. 1,035,019 shares of the company were exchanged, compared to its average volume of 955,103. The company has a 50 day moving average of $14.38 and a two-hundred day moving average of $14.40. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of -15.40 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a 52-week low of $10.90 and a 52-week high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.58. The business had revenue of $93.76 million during the quarter, compared to analyst estimates of $15.05 million. During the same quarter last year, the firm posted ($0.54) EPS. On average, equities research analysts predict that Day One Biopharmaceuticals, Inc. will post -0.97 EPS for the current year.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. increased its holdings in Day One Biopharmaceuticals by 38.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after acquiring an additional 1,002 shares during the period. Quest Partners LLC increased its stake in shares of Day One Biopharmaceuticals by 9,238.6% in the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock worth $108,000 after acquiring an additional 7,668 shares in the last quarter. SG Americas Securities LLC bought a new stake in Day One Biopharmaceuticals during the 2nd quarter valued at about $113,000. Point72 DIFC Ltd purchased a new position in shares of Day One Biopharmaceuticals in the second quarter worth approximately $124,000. Finally, Hsbc Holdings PLC purchased a new position in Day One Biopharmaceuticals during the second quarter valued at approximately $163,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Analyst Upgrades and Downgrades

DAWN has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. Wedbush restated an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. JPMorgan Chase & Co. cut their price objective on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.